Welcome to our dedicated page for Syneos Health news (Ticker: SYNH), a resource for investors and traders seeking the latest updates and insights on Syneos Health stock.
Syneos Health (SYNH) is a leading provider of integrated clinical and commercial solutions for the biopharmaceutical industry. This page aggregates official press releases, regulatory filings, and material updates related to SYNH's operations and market position.
Investors and industry professionals will find timely updates on clinical trial milestones, strategic partnerships, and financial performance. Our curated collection ensures access to primary source information critical for informed decision-making in the evolving healthcare sector.
The repository includes updates on regulatory developments, service expansions, and leadership changes, maintained with strict adherence to factual reporting. Content is organized chronologically for efficient tracking of corporate developments.
Bookmark this page for streamlined access to SYNH's latest announcements. Combine regular monitoring with professional financial advice when evaluating investment opportunities in the dynamic biopharma services market.
Syneos Health (Nasdaq:SYNH) will announce its third quarter 2020 financial results on October 29, 2020, before the earnings call at 8:00 a.m. ET. The call will be accessible via webcast on the company's Investor Relations website or by phone using the designated numbers. An audio replay will be available for a week post-call. Syneos Health is a fully integrated biopharmaceutical solutions organization with a global reach, combining clinical and commercial expertise to expedite the delivery of therapies to patients.
Syneos Health (Nasdaq: SYNH) announced a secondary offering of 7,000,000 shares at $59.75 per share, with an expected close on September 17, 2020. The sale is led by affiliates of Thomas H. Lee Partners and Advent International, with Syneos not receiving any proceeds from the offering. The company also agreed to repurchase approximately $30 million worth of its shares from the underwriters at the same share price. Goldman Sachs & Co. LLC and Morgan Stanley are the underwriters for this offering.
On September 15, 2020, Syneos Health (SYNH) announced a secondary offering of 7,000,000 shares of its common stock by affiliates of Thomas H. Lee Partners and Advent International. The company will not sell any shares or receive proceeds from this offering. It has agreed to repurchase approximately $30 million of the shares from the underwriters at the offering price. Goldman Sachs and Morgan Stanley are the underwriters for the transaction. Investors are encouraged to review the registration statements and prospectus available on the SEC website for further information.
MORRISVILLE, N.C., Sept. 9, 2020 – Syneos Health (Nasdaq: SYNH) announced a rescheduling of its presentation at the Baird 2020 Global Healthcare Conference due to technical glitches. CEO Alistair Macdonald and CFO Jason Meggs will present today at 12:15 p.m. ET. A live webcast and presentation materials will be available on the Company’s Investor Relations website, enhancing accessibility for stakeholders.
Syneos Health is a fully integrated biopharmaceutical solutions organization, combining a CRO and CCO, dedicated to improving customer performance globally.
Syneos Health (Nasdaq: SYNH) announced that CEO Alistair Macdonald and CFO Jason Meggs will present at the Baird 2020 Global Healthcare Conference on September 9, 2020, at 8:30 a.m. ET. A live webcast of the event, along with presentation materials and an archived audio replay, will be accessible on the Company's Investor Relations website.
Syneos Health is a fully integrated biopharmaceutical solutions organization, combining a Contract Research Organization (CRO) and a Contract Commercial Organization (CCO), serving over 110 countries with approximately 24,000 professionals.
Syneos Health (SYNH) reported a GAAP revenue of $1,013.4 million for Q2 2020, down 13.1% year-over-year. Net new business awards totaled $1,360.9 million, resulting in a book-to-bill ratio of 1.34x. The Clinical Solutions segment saw a revenue decline of 12.1% to $747.2 million, while Commercial Solutions dropped 16.0% to $266.2 million. Despite challenges from COVID-19, the company issued full-year guidance of $4,470 million to $4,570 million in revenue, along with adjusted EBITDA expectations of $600 million to $640 million.
Syneos Health (Nasdaq: SYNH) has signed a new three-year agreement with Pfizer to provide global product development solutions. This partnership strengthens their existing relationship, with a provision for Pfizer to extend the agreement by two additional years. Financial details are undisclosed. The collaboration will leverage Syneos Health's therapeutic expertise to optimize Pfizer's portfolio, ensuring efficient product development and trial processes.
Syneos Health (Nasdaq: SYNH) will announce its second quarter 2020 financial results on August 6, 2020, before an earnings call at 8:00 a.m. ET. The call can be accessed via webcast on the company's website or by telephone. Syneos Health, a fully integrated biopharmaceutical solutions organization, aims to enhance customer performance in over 110 countries, utilizing advanced technologies and insights to expedite crucial therapies to patients. A replay of the call will be available shortly after, along with audio access for a week.
MORRISVILLE, N.C., May 22, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq: SYNH) announced that CEO Alistair Macdonald and CFO Jason Meggs will present at two investor conferences. The events are the Jefferies Virtual Healthcare Conference on June 3, 2020, at 9:30 a.m. ET, and the William Blair 40th Annual Growth Stock Conference on June 9, 2020, at 9:00 a.m. ET. Live webcasts and presentation materials will be available on the Company’s Investor Relations website.
Syneos Health is a fully integrated biopharmaceutical solutions organization, combining a CRO and CCO.
FAQ
What is the market cap of Syneos Health (SYNH)?
